Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | conserved hypothetical protein | 0.0473 | 0.1584 | 0.2844 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0473 | 0.1584 | 0.2844 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0603 | 0.2185 | 0.3922 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0603 | 0.2185 | 0.3922 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0473 | 0.1584 | 0.2844 |
Brugia malayi | neuroendocrine convertase 1 precursor | 0.1723 | 0.7361 | 0.7356 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0473 | 0.1584 | 0.2844 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0603 | 0.2185 | 0.3922 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.1335 | 0.557 | 1 |
Echinococcus multilocularis | proprotein convertase subtilisin:kexin type 5 | 0.1335 | 0.557 | 0.712 |
Echinococcus multilocularis | Furin 1 | 0.0603 | 0.2185 | 0.2778 |
Loa Loa (eye worm) | endoprotease bli-4 | 0.2294 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0473 | 0.1584 | 0.2844 |
Echinococcus granulosus | furin | 0.2294 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0473 | 0.1584 | 0.2844 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0473 | 0.1584 | 0.2844 |
Brugia malayi | proprotein convertase 2 | 0.1561 | 0.6615 | 0.6608 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.1335 | 0.557 | 1 |
Schistosoma mansoni | subfamily S8B non-peptidase homologue (S08 family) | 0.0603 | 0.2185 | 0.2185 |
Echinococcus multilocularis | 0.1821 | 0.7815 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.2294 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0984 | 0.3947 | 0.3936 |
Brugia malayi | celfurPC protein | 0.1821 | 0.7815 | 0.7811 |
Schistosoma mansoni | subfamily S8B unassigned peptidase (S08 family) | 0.2294 | 1 | 1 |
Trichomonas vaginalis | hypothetical protein | 0.0473 | 0.1584 | 0.2844 |
Echinococcus multilocularis | neuroendocrine convertase 2 | 0.1561 | 0.6615 | 0.846 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0473 | 0.1584 | 0.2844 |
Trichomonas vaginalis | leucine-rich repeat protein, BspA family | 0.0473 | 0.1584 | 0.2844 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0473 | 0.1584 | 0.2844 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0473 | 0.1584 | 0.2844 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0603 | 0.2185 | 0.3922 |
Trichomonas vaginalis | neuroendocrine convertase 2 precursor, putative | 0.0498 | 0.1702 | 0.3056 |
Trichomonas vaginalis | proprotein convertase subtilisin/kexin type, putative | 0.0498 | 0.1702 | 0.3056 |
Schistosoma mansoni | tyrosine kinase | 0.0134 | 0.0019 | 0.0019 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0473 | 0.1584 | 0.2844 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0603 | 0.2185 | 0.3922 |
Loa Loa (eye worm) | proprotein convertase 2 | 0.0603 | 0.2185 | 0.217 |
Giardia lamblia | High cysteine membrane protein Group 2 | 0.0758 | 0.2903 | 1 |
Echinococcus granulosus | neuroendocrine convertase 2 | 0.1561 | 0.6615 | 0.6608 |
Echinococcus granulosus | proprotein convertase subtilisin:kexin type 5 | 0.1335 | 0.557 | 0.5562 |
Schistosoma mansoni | hypothetical protein | 0.0473 | 0.1584 | 0.1584 |
Loa Loa (eye worm) | hypothetical protein | 0.0187 | 0.0264 | 0.0246 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0603 | 0.2185 | 0.3922 |
Schistosoma mansoni | furin-1 (S08 family) | 0.1063 | 0.4312 | 0.4312 |
Echinococcus granulosus | Furin 1 | 0.0603 | 0.2185 | 0.217 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.